Current or past diagnoses of other Axis I psychiatric disorders, except for generalized anxiety disorder (GAD) symptoms occurring during a depressive episode
History of alcohol or drug dependence or abuse in the last three years
History of developmental disorder or IQ score < 70
Presence of acute suicidality
Acute grief (< 1 month)
Current or past psychosis
Primary neurological disorder, including but not limited to dementia, stroke, brain tumors, epilepsy, Parkinson's disease, or demyelinating diseases
MRI contraindications
Any physical or intellectual disability adversely affecting ability to complete assessments
Electroconvulsive therapy in last 6 months
Use of antidepressant medications or other psychotropic medications in the last 4 weeks (or the last 6 weeks for fluoxetine). Occasional use of benzodiazepines or non-benzodiazepine sedatives (such as zolpidem, eszopiclone, or zaleplon) during this period is allowable.
A failed therapeutic trial of escitalopram in the current depressive episode (defined as at least 6 weeks of treatment at a daily dose of 10mg or higher)
Known allergy or hypersensitivity to escitalopram or bupropion
Current or planned psychotherapy

NCT02332291_exc_T1
Qualifier
other
NCT02332291_exc_T2
Condition
Axis I psychiatric disorders
NCT02332291_exc_T3
Negation
except for
NCT02332291_exc_T4
Condition
generalized anxiety disorder (GAD)
NCT02332291_exc_T5
Temporal
during a depressive episode
NCT02332291_exc_T6
Reference_point
depressive episode
NCT02332291_exc_T7
Condition
depressive episode
NCT02332291_exc_T8
Condition
drug dependence
NCT02332291_exc_T9
Condition
lcohol ependence
NCT02332291_exc_T10
Condition
rug buse
NCT02332291_exc_T11
Condition
lcohol buse
NCT02332291_exc_T12
Temporal
in the last three years
NCT02332291_exc_T13
Scope
alcohol or drug dependence or abuse
NCT02332291_exc_T14
Condition
developmental disorder
NCT02332291_exc_T15
Measurement
IQ score
NCT02332291_exc_T16
Value
< 70
NCT02332291_exc_T17
Condition
acute suicidality
NCT02332291_exc_T18
Condition
Acute grief
NCT02332291_exc_T19
Temporal
< 1 month
NCT02332291_exc_T20
Condition
psychosis
NCT02332291_exc_T21
Temporal
past
NCT02332291_exc_T22
Temporal
Current
NCT02332291_exc_T23
Scope
Current or past
NCT02332291_exc_T24
Condition
Primary neurological disorder
NCT02332291_exc_T25
Condition
dementia
NCT02332291_exc_T26
Condition
stroke
NCT02332291_exc_T27
Condition
brain tumors
NCT02332291_exc_T28
Condition
epilepsy
NCT02332291_exc_T29
Condition
Parkinson's disease
NCT02332291_exc_T30
Condition
demyelinating diseases
NCT02332291_exc_T31
Scope
dementia, stroke, brain tumors, epilepsy, Parkinson's disease, or demyelinating diseases
NCT02332291_exc_T32
Procedure
MRI
NCT02332291_exc_T33
Condition
contraindications
NCT02332291_exc_T34
Condition
intellectual disability
NCT02332291_exc_T35
Condition
 or int ty adverse
NCT02332291_exc_T36
Procedure
Electroconvulsive therapy
NCT02332291_exc_T37
Temporal
in last 6 months
NCT02332291_exc_T38
Drug
antidepressant medications
NCT02332291_exc_T39
Qualifier
other
NCT02332291_exc_T40
Drug
psychotropic medications
NCT02332291_exc_T41
Temporal
in the last 4 weeks
NCT02332291_exc_T42
Temporal
t  weeks for fluo
NCT02332291_exc_T43
Drug
fluoxetine
NCT02332291_exc_T44
Scope
in the last 4 weeks (or the last 6 weeks for fluoxetine)
NCT02332291_exc_T45
Scope
antidepressant medications or other psychotropic medications
NCT02332291_exc_T46
Multiplier
Occasional use
NCT02332291_exc_T47
Drug
pines or non-be (such as
NCT02332291_exc_T48
Drug
non-benzodiazepine sedatives
NCT02332291_exc_T49
Drug
zolpidem
NCT02332291_exc_T50
Drug
eszopiclone
NCT02332291_exc_T51
Drug
zaleplon
NCT02332291_exc_T52
Scope
zolpidem, eszopiclone, or zaleplon
NCT02332291_exc_T53
Negation
is allowable
NCT02332291_exc_T54
Scope
benzodiazepines or non-benzodiazepine sedatives
NCT02332291_exc_T55
Drug
escitalopram
NCT02332291_exc_T56
Procedure
therapeutic trial
NCT02332291_exc_T57
Qualifier
failed
NCT02332291_exc_T58
Temporal
in the current depressive episode
NCT02332291_exc_T59
Reference_point
depressive episode
NCT02332291_exc_T60
Condition
depressive episode
NCT02332291_exc_T61
Temporal
at least 6 weeks of treatment
NCT02332291_exc_T62
Multiplier
daily dose of 10mg or higher
NCT02332291_exc_T63
Scope
at least 6 weeks of treatment at a daily dose of 10mg or higher
NCT02332291_exc_T64
Condition
allergy
NCT02332291_exc_T65
Condition
hypersensitivity
NCT02332291_exc_T66
Drug
escitalopram
NCT02332291_exc_T67
Drug
bupropion
NCT02332291_exc_T68
Scope
allergy or hypersensitivity
NCT02332291_exc_T69
Scope
escitalopram or bupropion
NCT02332291_exc_T70
Mood
planned
NCT02332291_exc_T71
Temporal
Current
NCT02332291_exc_T72
Procedure
psychotherapy
NCT02332291_exc_T73
Scope
Current or planned